Aikeremujiang Muheremu1,2, Tianlin Wen3, Xiaohui Niu2. 1. Department of Spine Surgery, Sixth Affiliated Hosptial of Xinjiang Medical University, Urumqi, Xinjiang, China. 2. Department of Orthopedic Oncology Surgery, Beijing Jishuitan Hospital, Beijing, China. 3. Department of Orthopaedics, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Abstract
OBJECTIVE: The current study was carried out to assess the value of positron emission tomography (PET)/CT on the diagnosis and staging of primary musculoskeletal tumors. METHODS: PET-CT test results and histopathological study reports of all the patients with primary musculoskeletal tumors in our department from January 2006 to July 2015 were retrospectively reviewed. Maximum standardized uptake value (SUVmax) in these PET-CT reports were recorded and analyzed respectively for each type of sarcoma. RESULTS: A total of 255 patients were included in the final analysis. Sensitivity of SUVmax based diagnosis was 96.6% for primary malignant osseous sarcomas and 91.2% for soft tissue sarcomas. SUVmax of high-grade osseous sarcomas (average 8.4 ± 5.5) was significantly higher (p < 0.001) than low-grade osseous sarcomas (average 3.9 ± 1.8); based on current case series, SUVmax of high-grade soft tissue sarcomas (7.5 ± 5.1) was not significantly different (p = 0.229) from that of low-grade soft tissue sarcomas (5.3 ± 3.7). Significant decrease of SUVmax value after chemotherapy was associated with favorable prognosis in patients with osteosarcoma. CONCLUSION: Results of the current study indicate that, the SUVmax based application of PET-CT can be a valuable supplementary method to histopathological tests regarding the diagnosis and staging of primary musculoskeletal sarcomas. ADVANCES IN KNOWLEDGE: SUVmax based application of PET-CT is a highly sensitive method in diagnosis of primary osseous and soft tissue sarcomas in Chinese patients.
OBJECTIVE: The current study was carried out to assess the value of positron emission tomography (PET)/CT on the diagnosis and staging of primary musculoskeletal tumors. METHODS: PET-CT test results and histopathological study reports of all the patients with primary musculoskeletal tumors in our department from January 2006 to July 2015 were retrospectively reviewed. Maximum standardized uptake value (SUVmax) in these PET-CT reports were recorded and analyzed respectively for each type of sarcoma. RESULTS: A total of 255 patients were included in the final analysis. Sensitivity of SUVmax based diagnosis was 96.6% for primary malignant osseous sarcomas and 91.2% for soft tissue sarcomas. SUVmax of high-grade osseous sarcomas (average 8.4 ± 5.5) was significantly higher (p < 0.001) than low-grade osseous sarcomas (average 3.9 ± 1.8); based on current case series, SUVmax of high-grade soft tissue sarcomas (7.5 ± 5.1) was not significantly different (p = 0.229) from that of low-grade soft tissue sarcomas (5.3 ± 3.7). Significant decrease of SUVmax value after chemotherapy was associated with favorable prognosis in patients with osteosarcoma. CONCLUSION: Results of the current study indicate that, the SUVmax based application of PET-CT can be a valuable supplementary method to histopathological tests regarding the diagnosis and staging of primary musculoskeletal sarcomas. ADVANCES IN KNOWLEDGE: SUVmax based application of PET-CT is a highly sensitive method in diagnosis of primary osseous and soft tissue sarcomas in Chinese patients.
Authors: K Strobel; U E Exner; K D M Stumpe; T F Hany; B Bode; K Mende; P Veit-Haibach; G K von Schulthess; Juerg Hodler Journal: Eur J Nucl Med Mol Imaging Date: 2008-08-20 Impact factor: 9.236
Authors: Lucas Goense; Peter S N van Rossum; Johannes B Reitsma; Marnix G E H Lam; Gert J Meijer; Marco van Vulpen; Jelle P Ruurda; Richard van Hillegersberg Journal: J Nucl Med Date: 2015-05-07 Impact factor: 10.057
Authors: Hugo J A Adams; John M H de Klerk; Ben G F Heggelman; Stefan V Dubois; Thomas C Kwee Journal: Eur J Nucl Med Mol Imaging Date: 2016-01-04 Impact factor: 9.236
Authors: Behrang Amini; John E Madewell; Hubert H Chuang; Tamara Miner Haygood; Brian P Hobbs; Patricia S Fox; Roland L Bassett; Colleen M Costelloe Journal: J Cancer Date: 2014-03-22 Impact factor: 4.207